US 12,234,289 B2
Immunosuppresive agent
Taku Okazaki, Tokushima (JP); Daisuke Sugiura, Tokushima (JP); Takeo Maeda, Tokushima (JP); and Shiro Shibayama, Ibaraki (JP)
Assigned to ONO PHARMACEUTICAL CO., LTD., Osaka (JP); and TOKUSHIMA UNIVERSITY, Tokushima (JP)
Appl. No. 17/311,148
Filed by ONO PHARMACEUTICAL CO., LTD., Osaka (JP); and TOKUSHIMA UNIVERSITY, Tokushima (JP)
PCT Filed Dec. 6, 2019, PCT No. PCT/JP2019/047913
§ 371(c)(1), (2) Date Jun. 4, 2021,
PCT Pub. No. WO2020/116636, PCT Pub. Date Jun. 11, 2020.
Claims priority of application No. 2018-229774 (JP), filed on Dec. 7, 2018.
Prior Publication US 2022/0025051 A1, Jan. 27, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 37/06 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 37/06 (2018.01); A61K 2039/505 (2013.01); C07K 2317/92 (2013.01)] 12 Claims
OG exemplary drawing
 
1. An anti-CD80 antibody comprising:
a heavy chain variable region that includes a heavy chain CDR1 including the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 including the amino acid sequence of SEQ ID NO: 10, and a heavy chain CDR3 including the amino acid sequence of SEQ ID NO: 11, and
a light chain variable region that includes a light chain CDR1 including the amino acid sequence of SEQ ID NO: 12, a light chain CDR2 including the amino acid sequence of SEQ ID NO: 13, and a light chain CDR3 including the amino acid sequence of SEQ ID NO: 14.